Blueberry Therapeutics

Blueberry Therapeutics is a drug discovery and development company specializing in polymer-drug delivery using a proprietary nanopolymer system. The platform self-assembles with both small and large molecules including proteins, peptides, and nucleic acids, packaging them into nanoparticles that enhance cellular delivery into mammalian and bacterial cells. The company is developing OTC and prescription products to treat infectious and inflammatory diseases including onychomycosis (fungal nail infection), tinea pedis (athlete's foot), acne, and acute wound care. The nanopolymer drug delivery technology addresses formulation challenges for difficult-to-deliver therapeutics, improving bioavailability, targeting, and therapeutic efficacy while reducing side effects. The platform's versatility enables applications across dermatology, anti-infectives, and inflammatory conditions, with products advancing through clinical development pipelines. Founded in 2011 and headquartered in Alderley Edge, United Kingdom, the company has raised approximately $23.8M in Series B funding from investors including Maven Capital Partners, Medical Incubator Japan, China Medical System, Catapult Ventures, and Northern Powerhouse Investment Fund.